Interim earnings of Rmb405m (+5% y-o-y) basically in line with consensus (Rmb398m)
Expect 10% earnings CAGR (2013-16F) on penetration into drug store market
However, most products are facing price-cutting risks Maintain HOLD with TP unchanged at HK$15.00